Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Enzastaurin Before and Concomitant With Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma Without Methylation of the Promoter Gene of MGMT Enzyme - a Phase II Study

    Summary
    EudraCT number
    2007-000281-21
    Trial protocol
    DE  
    Global end of trial date
    04 Jul 2008

    Results information
    Results version number
    v1(current)
    This version publication date
    15 Jun 2018
    First version publication date
    15 Jun 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    H6Q-MC-S039
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00509821
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    Trial Number: 11491
    Sponsors
    Sponsor organisation name
    Eli Lilly and Company
    Sponsor organisation address
    Lilly Corporate Center , Indianapolis, IN, United States, 46285
    Public contact
    Available Mon-Fri 9 AM-5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
    Scientific contact
    Available Mon-Fri 9 AM-5 PM EST, Eli Lilly and Company, 1 877-285-4559,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    04 Jul 2008
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    04 Jul 2008
    Global end of trial reached?
    Yes
    Global end of trial date
    04 Jul 2008
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The purpose of the protocol was to induce a novel radiochemotherapy with enzastaurin as first-line treatment regimen in glioblastoma: Participants with active, unmethylated MGMT promoter were treated with enzastaurin before, concomitant, and after radiotherapy to determine safety and PFS at 6 months (PFS-6) in phase II.
    Protection of trial subjects
    This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    12 Aug 2004
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 60
    Worldwide total number of subjects
    60
    EEA total number of subjects
    60
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    48
    From 65 to 84 years
    12
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    No text entered

    Pre-assignment
    Screening details
    Completers are participants who had failure event(progressive disease, death), or off treatment or censored. Participants completed follow-up after receiving 1 dose of study drug and a post dose efficacy evaluation. 3 participants received 1125 mg loading dose then 500 mg PO once daily but were not included or analyzed,but AEs are reported.

    Period 1
    Period 1 title
    Overall Ezastaurin BID (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Enzastaurin Twice a Day (BID)
    Arm description
    Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO.
    Arm type
    Experimental

    Investigational medicinal product name
    Enzastaurin
    Investigational medicinal product code
    Other name
    LY317615
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1125 mg loading dose D(-)7 then 250 mg Twice Daily BID.

    Number of subjects in period 1 [1]
    Enzastaurin Twice a Day (BID)
    Started
    57
    Induction
    57
    Radiation
    53
    Maintenance
    49 [2]
    Follow UP
    50
    Completed
    50
    Not completed
    7
         Adverse event, serious fatal
    5
         Progressive disease
    2
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: 3 participants received Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy. These 3 were not analyzed for any endpoints, but Adverse Events and Serious Adverse Events were reported.
    [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Participants did not have to enter into every milestone in the study to proceed to a different milestone and receive study drug.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Enzastaurin Twice a Day (BID)
    Reporting group description
    Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO.

    Reporting group values
    Enzastaurin Twice a Day (BID) Total
    Number of subjects
    57 57
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    45 45
        From 65-84 years
    12 12
        85 years and over
    0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    55.6 ± 11.29 -
    Gender categorical
    Units: Subjects
        Female
    21 21
        Male
    36 36
    Sex: Female, Male
    Units: Subjects
        Female
    21 21
        Male
    36 36
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    0 0
        Not Hispanic or Latino
    57 57
        Unknown or Not Reported
    0 0
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0
        Asian
    0 0
        Native Hawaiian or Other Pacific Islander
    0 0
        Black or African American
    0 0
        White
    57 57
        More than one race
    0 0
        Unknown or Not Reported
    0 0
    Region of Enrollment
    Units: Subjects
        Germany
    57 57

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Enzastaurin Twice a Day (BID)
    Reporting group description
    Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO.

    Subject analysis set title
    Mini Mental Questionnaire Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    All participants who received at least 1 dose of study drug and had evaluable data .

    Primary: Progression Free Survival Rate 6 Months (PFS-6)

    Close Top of page
    End point title
    Progression Free Survival Rate 6 Months (PFS-6) [1]
    End point description
    PFS-6 is defined as the rate of PFS at 6 months from the date of diagnosis to the first date of objectively determined progressive disease (based on radiological assessment) or death from any cause. It is assumed that PFS follows an exponential distribution.
    End point type
    Primary
    End point timeframe
    Baseline to 6 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This is a single arm study with no comparison groups.
    End point values
    Enzastaurin Twice a Day (BID)
    Number of subjects analysed
    57
    Units: Months
        number (confidence interval 95%)
    53.6 (39.8 to 65.6)
    No statistical analyses for this end point

    Secondary: Overall Survival at 1 and 2 Years After Surgery

    Close Top of page
    End point title
    Overall Survival at 1 and 2 Years After Surgery
    End point description
    Overall survival (OS) time is defined as the time from the date of diagnosis to the date of death from any cause. For participants who are still alive at the time of analysis, survival time will be censored at the last contact date. OS rate at 1 year (respectively 2 years) is determined using the OS times.
    End point type
    Secondary
    End point timeframe
    Baseline to 1 and 2 year
    End point values
    Enzastaurin Twice a Day (BID)
    Number of subjects analysed
    57
    Units: percent
    number (confidence interval 95%)
        1 year
    63.0 (49.1 to 74.1)
        2 year
    27.0 (16.2 to 39.0)
    No statistical analyses for this end point

    Secondary: Response Rate

    Close Top of page
    End point title
    Response Rate
    End point description
    Response rate is calculated as the number of participants with best response: complete response(CR: disappearance of all enhancing tumor on consecutive CT or magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved ) or partial response (PR:-50% reduction in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved), divided by the number of participants treated, multiplied by 100. CR and PR were assessed according to the criteria defined by MacDonald et al. 1990. A CR or PR must be confirmed by a second assessment, performed ≥28 days after the first evidence of response.
    End point type
    Secondary
    End point timeframe
    Baseline to 30 months
    End point values
    Enzastaurin Twice a Day (BID)
    Number of subjects analysed
    57
    Units: percent
        number (confidence interval 95%)
    7.0 (2.0 to 17.0)
    No statistical analyses for this end point

    Secondary: Change in Neurologic Status as Measured by Mini Mental Status Questionnaire, Total Score

    Close Top of page
    End point title
    Change in Neurologic Status as Measured by Mini Mental Status Questionnaire, Total Score
    End point description
    Mini Mental State Status questionnaire is 11 questions, total score can range from 0 to 30, with a higher score indicating better function and a negative change in baseline indicating decrease in cognitive function.
    End point type
    Secondary
    End point timeframe
    Baseline through Week 12 .
    End point values
    Mini Mental Questionnaire Set
    Number of subjects analysed
    56 [2]
    Units: units on a scale
        arithmetic mean (standard deviation)
    28.3 ± 4.86
    Notes
    [2] - Participants had to have completed the evaluation form.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Entire Study
    Adverse event reporting additional description
    H6Q-MC-S039
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.0
    Reporting groups
    Reporting group title
    ENZASTAURIN QD Induction
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN BID Induction
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN QD Radiation
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN BID Radiation
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN QD Maintenance
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN BID Maintenance
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN QD Overall
    Reporting group description
    -

    Reporting group title
    ENZASTAURIN BID Overall
    Reporting group description
    -

    Serious adverse events
    ENZASTAURIN QD Induction ENZASTAURIN BID Induction ENZASTAURIN QD Radiation ENZASTAURIN BID Radiation ENZASTAURIN QD Maintenance ENZASTAURIN BID Maintenance ENZASTAURIN QD Overall ENZASTAURIN BID Overall
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 3 (0.00%)
    5 / 57 (8.77%)
    0 / 3 (0.00%)
    16 / 53 (30.19%)
    0 / 3 (0.00%)
    8 / 49 (16.33%)
    0 / 3 (0.00%)
    27 / 57 (47.37%)
         number of deaths (all causes)
    0
    1
    0
    5
    0
    0
    0
    7
         number of deaths resulting from adverse events
    0
    1
    0
    2
    0
    0
    0
    3
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    intracranial tumour haemorrhage
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    Vascular disorders
    deep vein thrombosis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    2 / 3
    0 / 0
    0 / 0
    0 / 0
    2 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    haemorrhage
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    thrombosis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    fatigue
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    2 / 53 (3.77%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    2 / 57 (3.51%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    general physical health deterioration
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    impaired healing
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    soft tissue inflammation
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    1 / 49 (2.04%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    pneumonia aspiration
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    pulmonary embolism
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    2 / 57 (3.51%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    hepatic enzyme increased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    ventricular fibrillation
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Nervous system disorders
    brain oedema
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    cerebrospinal fluid leakage
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    1 / 49 (2.04%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    dizziness
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    epilepsy
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    generalised tonic-clonic seizure
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    hemiparesis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    2 / 49 (4.08%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 2
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    intracranial pressure increased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    partial seizures
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    seizure
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    2 / 53 (3.77%)
    0 / 3 (0.00%)
    4 / 49 (8.16%)
    0 / 3 (0.00%)
    6 / 57 (10.53%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 7
    0 / 0
    1 / 9
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    anaemia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    leukopenia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    thrombocytopenia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    2 / 57 (3.51%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    vertigo
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    1 / 49 (2.04%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    diarrhoea
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    1 / 49 (2.04%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    nausea
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    2 / 57 (3.51%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    pancreatitis necrotising
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    vomiting
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    2 / 49 (4.08%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    renal failure
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    neck pain
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    pain in extremity
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    bronchopulmonary aspergillosis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    cerebral aspergillosis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    cystitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    empyema
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    erysipelas
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    pneumocystis jirovecii infection
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    pneumonia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    2 / 3
    0 / 0
    0 / 0
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    sepsis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 57 (1.75%)
    0 / 3 (0.00%)
    2 / 53 (3.77%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    sinusitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    1 / 49 (2.04%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    wound infection
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    hyperkalaemia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    1 / 57 (1.75%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    ENZASTAURIN QD Induction ENZASTAURIN BID Induction ENZASTAURIN QD Radiation ENZASTAURIN BID Radiation ENZASTAURIN QD Maintenance ENZASTAURIN BID Maintenance ENZASTAURIN QD Overall ENZASTAURIN BID Overall
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    3 / 3 (100.00%)
    22 / 57 (38.60%)
    3 / 3 (100.00%)
    43 / 53 (81.13%)
    3 / 3 (100.00%)
    28 / 49 (57.14%)
    3 / 3 (100.00%)
    50 / 57 (87.72%)
    Vascular disorders
    hypertension
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    1 / 57 (1.75%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    1
    General disorders and administration site conditions
    fatigue
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    4 / 57 (7.02%)
    0 / 3 (0.00%)
    5 / 53 (9.43%)
    0 / 3 (0.00%)
    3 / 49 (6.12%)
    0 / 3 (0.00%)
    13 / 57 (22.81%)
         occurrences all number
    0
    4
    0
    5
    0
    3
    0
    13
    oedema peripheral
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    5
    pyrexia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    1 / 3 (33.33%)
    2 / 49 (4.08%)
    1 / 3 (33.33%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    1
    3
    Respiratory, thoracic and mediastinal disorders
    cough
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    4
    epistaxis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    Psychiatric disorders
    agitation
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    0
    confusional state
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3
    depression
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    3 / 49 (6.12%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    0
    3
    irritability
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    Investigations
    alanine aminotransferase increased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    4 / 53 (7.55%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    5 / 57 (8.77%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    0
    5
    blood creatinine increased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3
    electrocardiogram qt prolonged
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    6
    haemoglobin decreased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    4
    weight increased
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    2 / 57 (3.51%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    2
    Nervous system disorders
    aphasia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    2 / 57 (3.51%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    1
    2
    dizziness
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 57 (3.51%)
    1 / 3 (33.33%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    2 / 3 (66.67%)
    6 / 57 (10.53%)
         occurrences all number
    1
    2
    1
    3
    0
    0
    2
    7
    head discomfort
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    headache
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    2 / 3 (66.67%)
    10 / 53 (18.87%)
    0 / 3 (0.00%)
    3 / 49 (6.12%)
    2 / 3 (66.67%)
    14 / 57 (24.56%)
         occurrences all number
    0
    0
    2
    12
    0
    3
    2
    20
    peripheral motor neuropathy
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3
    seizure
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    6 / 49 (12.24%)
    0 / 3 (0.00%)
    9 / 57 (15.79%)
         occurrences all number
    0
    0
    0
    0
    0
    6
    0
    9
    somnolence
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    2 / 57 (3.51%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    2
    Blood and lymphatic system disorders
    leukopenia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    1 / 3 (33.33%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    1 / 57 (1.75%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    1
    1
    lymphopenia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    4 / 53 (7.55%)
    1 / 3 (33.33%)
    1 / 49 (2.04%)
    1 / 3 (33.33%)
    7 / 57 (12.28%)
         occurrences all number
    0
    0
    0
    4
    1
    1
    1
    9
    Gastrointestinal disorders
    abdominal discomfort
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    4 / 57 (7.02%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    4
    constipation
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3
    diarrhoea
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    4 / 49 (8.16%)
    0 / 3 (0.00%)
    8 / 57 (14.04%)
         occurrences all number
    0
    0
    0
    3
    0
    4
    0
    8
    nausea
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    5 / 53 (9.43%)
    0 / 3 (0.00%)
    4 / 49 (8.16%)
    1 / 3 (33.33%)
    9 / 57 (15.79%)
         occurrences all number
    0
    0
    1
    5
    0
    4
    1
    11
    vomiting
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    7 / 49 (14.29%)
    0 / 3 (0.00%)
    9 / 57 (15.79%)
         occurrences all number
    0
    0
    0
    0
    0
    7
    0
    9
    Skin and subcutaneous tissue disorders
    alopecia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    3 / 3 (100.00%)
    12 / 53 (22.64%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    3 / 3 (100.00%)
    13 / 57 (22.81%)
         occurrences all number
    0
    0
    3
    12
    0
    0
    3
    13
    dermatitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    3 / 53 (5.66%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    1
    3
    0
    0
    1
    3
    pruritus
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    2
    0
    rash
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    1 / 3 (33.33%)
    1 / 49 (2.04%)
    1 / 3 (33.33%)
    2 / 57 (3.51%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    1
    2
    rash erythematous
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    1 / 53 (1.89%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    1 / 57 (1.75%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    1
    1
    Renal and urinary disorders
    chromaturia
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    3 / 3 (100.00%)
    9 / 57 (15.79%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    3 / 3 (100.00%)
    11 / 57 (19.30%)
         occurrences all number
    3
    9
    0
    0
    0
    0
    3
    11
    Musculoskeletal and connective tissue disorders
    back pain
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    1 / 3 (33.33%)
    2 / 49 (4.08%)
    1 / 3 (33.33%)
    4 / 57 (7.02%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    1
    5
    Infections and infestations
    cystitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    1 / 3 (33.33%)
    1 / 49 (2.04%)
    1 / 3 (33.33%)
    1 / 57 (1.75%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    1
    1
    gingivitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    1 / 57 (1.75%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    1
    nasopharyngitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    2 / 53 (3.77%)
    1 / 3 (33.33%)
    4 / 49 (8.16%)
    3 / 3 (100.00%)
    6 / 57 (10.53%)
         occurrences all number
    1
    0
    1
    2
    1
    10
    3
    13
    sinusitis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    4
    tinea pedis
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    1 / 3 (33.33%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    1 / 3 (33.33%)
    0 / 57 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    Metabolism and nutrition disorders
    decreased appetite
    alternative dictionary used: MedDRA 19.0
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 57 (0.00%)
    0 / 3 (0.00%)
    0 / 53 (0.00%)
    0 / 3 (0.00%)
    0 / 49 (0.00%)
    0 / 3 (0.00%)
    3 / 57 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    3

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    3 participants receiving 500 mg enzastaurin QD were not included in analysis for outcome measures per protocol but had AE/SAEs reported.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 11:05:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA